DOCSLIB.ORG

Safety Evaluation of Linear and Macrocyclic Gadolinium-Based

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Unique Protocol Identification Number: Gadolinium 1.0 Safety Evaluation of Linear and Macrocyclic Gadolinium-Based Contrast Agents for Patients with Mild to Moderate Renal Insufficiency Undergoing Enhanced Magnetic Resonance Imaging (Interventional Prospective Study) Clinical Trial Protocol Version number: V1.0 Version date: 2020-11 Catology Protocol Summary ............................................................................................................................ 2 Ⅰ. Sponsor Information ...................................................................................................................... 4 (Ⅰ) Name of sponsor .................................................................................................................. 4 (Ⅱ) Address of sponsor .............................................................................................................. 4 (Ⅲ) Contact information of sponsor ......................................................................................... 4 (Ⅳ) Relevant qualification documents of sponsor.................................................................... 4 Ⅱ. Purpose and contents of clinical trial ............................................................................................ 5 (Ⅰ) Purpose ................................................................................................................................. 5 (Ⅱ) Contents .............................................................................................................................. 5 Ⅲ. Background information of clinical trials ................................................................................... 5 Ⅳ. The characteristics and safety of the drug ................................................................................... 7 (Ⅰ) Characteristics of the drug ................................................................................................... 7 (Ⅱ) Safety data of clinical application so far ............................................................................. 8 Ⅴ. Indications, contraindications and precautions of drugs .............................................................. 9 Ⅵ. Overall design ............................................................................................................................. 9 (Ⅰ) Design of the trial ................................................................................................................. 9 (Ⅱ) Patient selection and withdrawal ...................................................................................... 10 (Ⅲ) Visit description ............................................................................................................... 11 (Ⅳ) Evaluation Standard ........................................................................................................ 13 Ⅶ. Trial quality control ................................................................................................................. 15 (Ⅰ) Quality Control .................................................................................................................. 15 (Ⅱ)Monitor .............................................................................................................................. 17 Ⅷ. Patient protection .................................................................................................................... 17 Ⅸ. Data management and statistical analysis ................................................................................. 17 (Ⅰ) Data management ............................................................................................................... 18 (Ⅱ)Statistical Analysis ............................................................................................................. 18 Ⅹ. Trial summary and results publication ....................................................................................... 19 1 Protocol Summary Safety Evaluation of Linear and Macrocyclic Gadolinium-Based Contrast Study Title Agents for Patients with Mild to Moderate Renal Insufficiency Undergoing Enhanced Magnetic Resonance Imaging Study Unit Lishui Central Hospital Study Type Interventional Time Perspective Prospective Gadodiamide Injection (OMNISCAN™), Study Drug Gadoteric Acid Meglumine Salt Injection (Jia Di Xian™) Brief Summary: The purpose of this study is to evaluate the safety of linear and macrocyclic gadolinium-based contrast agents for patients with mild to Study moderate renal insufficiency. The study will compare the incidence of Description adverse events of gadodiamide and gadoteric Acid Meglumine Salt for patients with mild to moderate renal insufficiency undergoing enhanced magnetic resonance imaging. Gadodiamide： Drug: Patients who have undergone Gadodiamide Injection contrast-enhanced MRI using (OMNISCAN™) Gadodiamide contrast agent for clinical purposes. Group/Cohort Gadoteric Acid Meglumine Salt： Drug: Patients who have undergone Gadoteric Acid Meglumine Salt contrast-enhanced MRI using Injection (Jia Di Xian™) Gadoteric Acid Meglumine Salt contrast agent for clinical purposes. Inclusion Criteria: 1. Patients aged 18 to 80 years old who require gadolinium-based CE-MRI; 2. Patients with renal function 30ml/min/1.73m2 ≤ eGFR ＜ Eligibility 90/min/1.73m2; Criteria 3. Patients who are able and willing to comply with the required inspection requirements. Exclusion Criteria: 1. Patient who experienced allergic reactions to previous gadolinium based contrast agents; 2 2. Patient who had used gadolinium based contrast agents within 3 months; 3. Patient with acute renal failure; 4. Patient who cannot comply with or cannot tolerate the necessary fluid replenishment procedures; 5. Patient with major mental illness, impaired consciousness or other diseases considered by researchers to affect observation. Primary Outcome indicators: Record the incidence of various adverse events; Secondary outcome indicators: Outcome 1. Changes of serum creatinine and inflammatory factors (TNF-α, hs-CRP, Measure IL-6) before and after CE-MRI 2. Patient skin examination and evaluation: evaluation of relevant indicators of skin biopsy (proliferation of fibroblasts in subcutaneous tissue, thickening of collagen fiber bundles) Enrollment 600 participants 3 Ⅰ. Sponsor Information (Ⅰ) Name of sponsor Jiansong, Ji (Ⅱ) Address of sponsor Lishui Central Hospital, No.289 Kuocang Road, Lishui City, Zhejiang Province (Ⅲ) Contact information of sponsor 0578-2285018 (Ⅳ) Relevant qualification documents of sponsor The relevant qualification documents of the sponsor will be provided in a separate letter. 4 Ⅱ. Purpose and contents of clinical trial (Ⅰ) Purpose To compare the incidence of adverse events of linear and macrocyclic gadolinium-based contrast agents for patients with mild to moderate renal insufficiency undergoing enhanced magnetic resonance imaging. (Ⅱ) Contents This trial is a prospective, interventional study. According to the requirements of the study, 600 cases of patients with mild to moderate renal insufficiency were enrolled. Gadodiamide and gadoteric acid meglumine salt were used for enhanced MRI. Observe the adverse reactions within 60 minutes of using the gadolinium contrast agents; follow up by telephone at 3, 6, 12, and 24 months after the inspection. Ⅲ. Background information of clinical trials The principle of Magnetic Resonance Imaging (MRI) relies on the magnetic field generated by water molecules in the human body. It has high resolution in soft tissues (such as the nervous system, parenchymal organs, and muscle tissue), and uses non-ionizing electromagnetic radiation. Known exposure risk, many imaging parameters (sequence, proton density, T1 and T2 relaxation time) and many other advantages, since it entered the clinic in the 1980s, it has been clinically proven to be a valuable imaging diagnostic method. In the early clinical practice, MRI was mainly used for unenhanced magnetic resonance imaging, and the value of Contrast Enhanced-Magnetic Resonance Imaging (CE-MRI) in the diagnosis of diseases was not recognized. In the later stage, due to CE-MRI in small lesions, inflammation, edema and tumor Such diagnostic advantages have become an important supplement to MRI. At least about 30% of disease MRI diagnosis requires injection of magnetic resonance contrast agents. In 2000, Cowper described the mucoedema-like sclerosis skin disease of renal dialysis patients in the Lancet magazine, that is, Nephrogenic Systemic Fibrosis (NSF). In 2006, Grobner 5 reported nephrogenic skin. The predisposing factor of disease or NSF may be gadolinium ion. In the same year, Marckmann discovered that NSF may be caused by the use of gadolinium diamine during MR examination. Due to the serious harm of NSF, foreign scholars began to pay explosive attention to the relationship between gadolinium contrast agent and NSF, and aroused clinical concern about the safety of gadolinium contrast agent. Subsequently, the European Society of Urology and Radiology (ESUR) classified gadolinium contrast agent as high-risk, medium-risk and low-risk , And use gadolinium contrast agent according to the classification of renal function. Since then, new reports of NSF have gradually decreased. Due to the long-term concern about the safety of gadolinium contrast agent, Dr. Tomonori Kanda published an article in the Journal of Radiology in Hyogo Cancer in 2014 and explained for the first time the relationship between T1 hyperintensity and gadolinium deposition
Recommended publications
  • Not for Immediate Release

    Not for Immediate Release

    Press Contact: David Pitts Argot Partners 212.600.1902 [email protected] Bracco Imaging Continues its Investment in Delivering Radiological Solutions Growing Breadth of Portfolio, Research, Education and Innovation Initiatives Highlighted at the 2011 RSNA CHICAGO, November 27, 2011 – Bracco Imaging S.p.A. – one of the world’s leading companies in the diagnostic imaging business and part of the Bracco Group – is highlighting the Company’s investment and commitment to imaging agents and radiology solutions across modalities through its growing product portfolio, as well as research, education and innovation, at the 97th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), which is being held November 27 - December 2, 2011 at Chicago’s McCormick Place, booth #4839. "Bracco remains committed to the diagnostic imaging sector, investing in imaging across modalities, including X-ray, Computed Tomography (CT), Cath Lab, Magnetic Resonance Imaging (MRI), Nuclear Medicine and Ultrasound," according to Fulvio Renoldi Bracco, head of Bracco Imaging, S.p.A. "In a difficult economic climate, where investing in the future is not top of mind, Bracco remains at the forefront. We believe that imaging agents and integrated imaging solutions are critical to support radiologists and other imaging specialists in making an effective diagnosis. Our commitment to providing the market with industry-leading products and solutions, and our partnership with the medical community, therefore remains unchanged." Fulvio Renoldi Bracco concluded: "We perceive this period in the industry, and indeed in the broader markets, as an opportunity to invest and to continue to deliver the best contrast imaging solutions to market.
  • List of Union Reference Dates A

    List of Union Reference Dates A

    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
  • Guideline on Core Smpc and Package Leaflet for Gadoteric Acid EMA/CHMP/337820/2016 Page 2/23

    Guideline on Core Smpc and Package Leaflet for Gadoteric Acid EMA/CHMP/337820/2016 Page 2/23

    1 26 May 2016 2 EMA/CHMP/337820/2016 3 Committee for Medicinal Products for Human Use (CHMP) 4 Guideline on core SmPC and Package Leaflet for gadoteric 5 acid 6 Draft Draft agreed by Radiopharmaceutical Drafting Group April 2016 Adopted by CHMP for release for consultation 26 May 2016 Start of public consultation 1 June 2016 End of consultation (deadline for comments) 30 September 2016 7 Comments should be provided using this template. The completed comments form should be sent to [email protected]. 8 Keywords Magnetic resonance, contrast media, gadolinium compounds, core SmPC, core Package Leaflet, gadoteric acid 9 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European Union © European Medicines Agency, 2016. Reproduction is authorised provided the source is acknowledged. 10 Guideline on core SmPC and Package Leaflet for gadoteric 11 acid 12 Table of contents 13 Executive summary ..................................................................................... 3 14 1. Introduction (background) ...................................................................... 3 15 2. Scope....................................................................................................... 3 16 3. Legal basis .............................................................................................. 3 17 4. Core SmPC and Package Leaflet for gadoteric acid .................................
  • Drug-Induced Anaphylaxis in China: a 10 Year Retrospective Analysis of The

    Drug-Induced Anaphylaxis in China: a 10 Year Retrospective Analysis of The

    Int J Clin Pharm DOI 10.1007/s11096-017-0535-2 RESEARCH ARTICLE Drug‑induced anaphylaxis in China: a 10 year retrospective analysis of the Beijing Pharmacovigilance Database Ying Zhao1,2,3 · Shusen Sun4 · Xiaotong Li1,3 · Xiang Ma1 · Huilin Tang5 · Lulu Sun2 · Suodi Zhai1 · Tiansheng Wang1,3,6 Received: 9 May 2017 / Accepted: 19 September 2017 © The Author(s) 2017. This article is an open access publication Abstract Background Few studies on the causes of (50.1%), mucocutaneous (47.4%), and gastrointestinal symp- drug-induced anaphylaxis (DIA) in the hospital setting are toms (31.3%). A total of 249 diferent drugs were involved. available. Objective We aimed to use the Beijing Pharma- DIAs were mainly caused by antibiotics (39.3%), traditional covigilance Database (BPD) to identify the causes of DIA Chinese medicines (TCM) (11.9%), radiocontrast agents in Beijing, China. Setting Anaphylactic case reports from (11.9%), and antineoplastic agents (10.3%). Cephalospor- the BPD provided by the Beijing Center for Adverse Drug ins accounted for majority (34.5%) of antibiotic-induced Reaction Monitoring. Method DIA cases collected by the anaphylaxis, followed by fuoroquinolones (29.6%), beta- BPD from January 2004 to December 2014 were adjudi- lactam/beta-lactamase inhibitors (15.4%) and penicillins cated. Cases were analyzed for demographics, causative (7.9%). Blood products and biological agents (3.1%), and drugs and route of administration, and clinical signs and plasma substitutes (2.1%) were also important contributors outcomes. Main outcome measure Drugs implicated in DIAs to DIAs. Conclusion A variety of drug classes were impli- were identifed and the signs and symptoms of the DIA cases cated in DIAs.
  • Radiopharmaceuticals and Contrast Media – Oxford Clinical Policy

    Radiopharmaceuticals and Contrast Media – Oxford Clinical Policy

    UnitedHealthcare® Oxford Clinical Policy Radiopharmaceuticals and Contrast Media Policy Number: RADIOLOGY 034.19 T0 Effective Date: January 1, 2021 Instructions for Use Table of Contents Page Related Policies Coverage Rationale ....................................................................... 1 • Cardiology Procedures Requiring Prior Definitions .................................................................................... 10 Authorization for eviCore Healthcare Arrangement Prior Authorization Requirements .............................................. 10 • Radiation Therapy Procedures Requiring Prior Applicable Codes ........................................................................ 10 Authorization for eviCore Healthcare Arrangement Description of Services ............................................................... 13 • Radiology Procedures Requiring Prior Authorization References ................................................................................... 13 for eviCore Healthcare Arrangement Policy History/Revision Information ........................................... 14 Instructions for Use ..................................................................... 14 Coverage Rationale eviCore healthcare administers claims on behalf of Oxford Health Plans for the following services that may be billed in conjunction with radiopharmaceuticals and/or contrast media: • Radiology Services: Refer to Radiology Procedures Requiring Prior Authorization for eviCore Healthcare Arrangement for additional information.
  • Harmonised Bds Suppl 20070

    Harmonised Bds Suppl 20070

    ABCDEF 1 EU Harmonised Birth Dates and related Data Lock Points, Supplementary list, 7 February 2007 Innovator brand name First DLP after Proposed Active substance name (INN) (for fixed combination 30 October Firm's Name Comments EU HBD products only) 2005 2 3 Aceclofenac 19900319 20080331 Almirall / UCB 4 Aciclovir 19810610 20060630 GSK 5 Adrafinil 19810710 20060131 Cephalon 6 Aldesleukine 19890703 20051231 Novartis NL=RMS Pfizer/Schwarz 7 Alprostadil (erectile dysfunction) 19840128 20080131 Pharma UK=RMS Alprostadil (peripheral arterial 19810723 20060731 Pfizer product differs from Schwarz Pharma 8 occlusive diseases) product Alprostadil (peripheral arterial 19841128 20051128 Schwarz Pharma product differs from Pfizer product 9 occlusive diseases) 10 Atenolol + chlorthalidone Tenoretic 19970909 20080908 AstraZeneca Azelaic acid 19881027 20060102 Schering AG / Pfizer AT = RMS 11 12 Aztreonam 19840804 20060803 BMS 13 Benazepril 19891128 20071130 Novartis Benazepril + hydrochlorothiazide Cibadrex 19920519 20070531 Novartis 14 15 Bisoprolol 19860128 20070930 Merck AG Bisoprolol + hydrochlorothiazide many product names 19920130 20061103 Merck AG 16 17 Botulinum Toxin A 19960906 20061030 Allergan currently 6-monthly PSURs 18 Brimonidine 19960906 20080930 Allergan UK=RMS 19 Brimonidine + timolol Combigan 19960906 20080930 Allergan UK=RMS 20 Bromperidol 20061115 J&J 21 Brotizolam 19830515 20071231 Boehringer Ingelheim 22 Budesonide 19920430 20070430 AstraZeneca 23 Budesonide + formoterol Symbicort 20000825 20070825 AstraZeneca 24 Buflomedil
  • ACR Manual on Contrast Media

    ACR Manual on Contrast Media

    ACR Manual On Contrast Media 2021 ACR Committee on Drugs and Contrast Media Preface 2 ACR Manual on Contrast Media 2021 ACR Committee on Drugs and Contrast Media © Copyright 2021 American College of Radiology ISBN: 978-1-55903-012-0 TABLE OF CONTENTS Topic Page 1. Preface 1 2. Version History 2 3. Introduction 4 4. Patient Selection and Preparation Strategies Before Contrast 5 Medium Administration 5. Fasting Prior to Intravascular Contrast Media Administration 14 6. Safe Injection of Contrast Media 15 7. Extravasation of Contrast Media 18 8. Allergic-Like And Physiologic Reactions to Intravascular 22 Iodinated Contrast Media 9. Contrast Media Warming 29 10. Contrast-Associated Acute Kidney Injury and Contrast 33 Induced Acute Kidney Injury in Adults 11. Metformin 45 12. Contrast Media in Children 48 13. Gastrointestinal (GI) Contrast Media in Adults: Indications and 57 Guidelines 14. ACR–ASNR Position Statement On the Use of Gadolinium 78 Contrast Agents 15. Adverse Reactions To Gadolinium-Based Contrast Media 79 16. Nephrogenic Systemic Fibrosis (NSF) 83 17. Ultrasound Contrast Media 92 18. Treatment of Contrast Reactions 95 19. Administration of Contrast Media to Pregnant or Potentially 97 Pregnant Patients 20. Administration of Contrast Media to Women Who are Breast- 101 Feeding Table 1 – Categories Of Acute Reactions 103 Table 2 – Treatment Of Acute Reactions To Contrast Media In 105 Children Table 3 – Management Of Acute Reactions To Contrast Media In 114 Adults Table 4 – Equipment For Contrast Reaction Kits In Radiology 122 Appendix A – Contrast Media Specifications 124 PREFACE This edition of the ACR Manual on Contrast Media replaces all earlier editions.
  • FDA Warns That Gadolinium-Based Contrast Agents (Gbcas) Are Retained in the Body; Requires New Class Warnings

    FDA Warns That Gadolinium-Based Contrast Agents (Gbcas) Are Retained in the Body; Requires New Class Warnings

    FDA warns that gadolinium-based contrast agents (GBCAs) are retained in the body; requires new class warnings This is an update to the FDA Drug Safety Communication: FDA identifies no harmful effects to date with brain retention of gadolinium-based contrast agents for MRIs; review to continue issued on May 22, 2017. Safety Announcement [12-19-2017] The U.S. Food and Drug Administration (FDA) is requiring a new class warning and other safety measures for all gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging (MRI) concerning gadolinium remaining in patients’ bodies, including the brain, for months to years after receiving these drugs. Gadolinium retention has not been directly linked to adverse health effects in patients with normal kidney function, and we have concluded that the benefit of all approved GBCAs continues to outweigh any potential risks. However, after additional review and consultation with the Medical Imaging Drugs Advisory Committee, we are requiring several actions to alert health care professionals and patients about gadolinium retention after an MRI using a GBCA, and actions that can help minimize problems. These include requiring a new patient Medication Guide, providing educational information that every patient will be asked to read before receiving a GBCA. We are also requiring manufacturers of GBCAs to conduct human and animal studies to further assess the safety of these contrast agents. GBCAs are used with medical imaging devices called MRI scanners to examine the body for problems such as cancer, infections, or bleeding. GBCAs contain gadolinium, a heavy metal. These contrast agents are injected into a vein to improve visualization of internal organs, blood vessels, and tissues during an MRI, which helps health care professionals diagnose medical conditions.
  • Gadolinium Based Contrast Agents

    Gadolinium Based Contrast Agents

    CE Credits Available CONSIDERATIONS IN THE SELECTION OF A NEW GADOLINIUM-BASED CONTRAST AGENT SUPPLEMENT TO MAY 2014 THE JOURNAL OF PRACTICAL MEDICAL IMAGING AND MANAGEMENT Considerations in the Selection of a New Gadolinium-Based Contrast Agent Michael F. Tweedle, PhD Emanuel Kanal, MD, FACR, FISMRM Robert Muller, PhD Stefanie Spielman Professor of Radiology Professor of Radiology and Neuroradiology Department of General, Organic & The Ohio State University University of Pittsburgh Medical Center Biochemical Chemistry Columbus, OH Pittsburgh, PA University of Mons Mons, Belgium Supported by an unrestricted educational grant from © May 2014 www.appliedradiology.com SUPPLEMENT TO APPLIED RADIOLOGY n 1 Publisher Kieran Anderson Executive Editor Cristen Bolan Art and Production Barbara A. Shopiro Applied Radiology and this supplement, Considerations in the Selection of a New Gadolinium-Based Contrast Agent, are published by Anderson Publishing, Ltd. The journal does not warrant the expertise of any author in a particular field, nor is it responsible for any statements by such authors. The opinions expressed in this supplement are those of the authors. They do not imply endorsement of advertised products and do not necessarily reflect the opinions or recommendations of our sponsors or the editors and staff of Applied Radiology. Copyright © 2014 by Anderson Publishing, Ltd., 180 Glenside Avenue, Scotch Plains, NJ 07076 All rights reserved. Cover images courtesy of Howard A. Rowley, MD. Considerations in the Selection of a New Gadolinium-Based Contrast Agent Our 3 esteemed faculty summarize the similarities and differences among the gadolinium-based contrast agents (GBCAs) currently utilized for magnetic resonance imaging (MRI), with emphasis on stability and relaxivity.
  • DISSERTATION INVESTIGATION of CATIONIC CONTRAST-ENHANCED COMPUTED TOMOGRAPHY for the EVALUATION of EQUINE ARTICULAR CARTILAGE Su

    DISSERTATION INVESTIGATION of CATIONIC CONTRAST-ENHANCED COMPUTED TOMOGRAPHY for the EVALUATION of EQUINE ARTICULAR CARTILAGE Su

    DISSERTATION INVESTIGATION OF CATIONIC CONTRAST-ENHANCED COMPUTED TOMOGRAPHY FOR THE EVALUATION OF EQUINE ARTICULAR CARTILAGE Submitted by Bradley B. Nelson Department of Clinical Sciences In partial fulfillment of the requirements For the Degree of Doctor of Philosophy Colorado State University Fort Collins, Colorado Fall 2017 Doctoral Committee: Advisor: Christopher E. Kawcak Co-Advisor: Laurie R. Goodrich C. Wayne McIlwraith Mark W. Grinstaff Myra F. Barrett Copyright by Bradley Bernard Nelson 2017 All Rights Reserved ABSTRACT INVESTIGATION OF CATIONIC CONTRAST-ENHANCED COMPUTED TOMOGRAPHY FOR THE EVALUATION OF EQUINE ARTICULAR CARTILAGE Osteoarthritis and articular cartilage injury are substantial problems in horses causing joint pain, lameness and decreased athleticism resonant of the afflictions that occur in humans. This debilitating joint disease causes progressive articular cartilage degeneration and coupled with a poor capacity to heal necessitates that articular cartilage injury is detected early before irreparable damage ensues. The use of diagnostic imaging is critical to identify and characterize articular cartilage injury, though currently available methods are unable to identify these early degenerative changes. Cationic contrast-enhanced computed tomography (CECT) uses a cationic contrast media (CA4+) to detect the early molecular changes that occur in the extracellular matrix. Glycosaminoglycans (GAGs) within the extracellular matrix are important for the providing the compressive stiffness of articular cartilage and their degradation is an early event in the development of osteoarthritis. Cationic CECT imaging capitalizes on the electrostatic attraction between CA4+ and GAGs; exposing the proportional relationship between the amount of GAGs present within and the amount of CA4+ that diffuses into the tissue. The amount of CA4+ that resides in the tissue is then quantified through CECT imaging and estimates tissue integrity through nondestructive assessment.
  • ACR Manual on Contrast Media – Version 9, 2013 Table of Contents / I

    ACR Manual on Contrast Media – Version 9, 2013 Table of Contents / I

    ACR Manual on Contrast Media Version 9 2013 ACR Committee on Drugs and Contrast Media ACR Manual on Contrast Media – Version 9, 2013 Table of Contents / i ACR Manual on Contrast Media Version 9 2013 ACR Committee on Drugs and Contrast Media © Copyright 2013 American College of Radiology ISBN: 978-1-55903-012-0 Table of Contents Topic Last Updated Page 1. Preface. V9 – 2013 . 3 2. Introduction . V7 – 2010 . 4 3. Patient Selection And Preparation Strategies . V7 – 2010 . 5 4. Injection of Contrast Media . V7 – 2010 . 13 5. Extravasation Of Contrast Media . V7 – 2010 . 17 6. Allergic-Like And Physiologic Reactions To Intravascular Iodinated Contrast Media . V9 – 2013 . 21 7. Contrast Media Warming . V8 – 2012 . 29 8. Contrast-Induced Nephrotoxicity . V8 – 2012 . 33 9. Metformin . V7 – 2010 . 43 10. Contrast Media In Children . V7 – 2010 . 47 11. Gastrointestinal (GI) Contrast Media In Adults: Indications And Guidelines V9 – 2013 . 55 12. Adverse Reactions To Gadolinium-Based Contrast Media . V7 – 2010 . 77 13. Nephrogenic Systemic Fibrosis . V8 – 2012 . 81 14. Treatment Of Contrast Reactions . V9 – 2013 . 91 15. Administration Of Contrast Media To Pregnant Or Potentially Pregnant Patients . V9 – 2013 . 93 16. Administration Of Contrast Media To Women Who Are Breast-Feeding . V9 – 2013 . 97 Table 1 – Indications for Use of Iodinated Contrast Media . V9 – 2013 . 99 Table 2 – Organ and System-Specific Adverse Effects from the Administration of Iodine-Based or Gadolinium-Based Contrast Agents. V9 – 2013 . 100 Table 3 – Categories of Acute Reactions . V9 – 2013 . 101 Table 4 – Treatment of Acute Reactions to Contrast Media in Children . V9 – 2013 .
  • Advisory Committee Briefing Document Medical Imaging Drugs Advisory Committee (MIDAC) September 8, 2017

    Advisory Committee Briefing Document Medical Imaging Drugs Advisory Committee (MIDAC) September 8, 2017

    Dotarem® (gadoterate meglumine) Injection – NDA# 204781 Advisory Committee Optimark® (gadoversetamide) Injection - NDAs# 020937, 020975 & 020976 Briefing Document Advisory Committee Briefing Document Medical Imaging Drugs Advisory Committee (MIDAC) September 8, 2017 DOTAREM® (gadoterate meglumine) Injection NDA 204781 Guerbet LLC, 821 Alexander Rd, Princeton, NJ 08540 OPTIMARK® (gadoversetamide) Injection NDAs 020937, 020975 & 020976 Liebel-Flarsheim Company LLC, 1034 Brentwood Blvd., Richmond Heights, MO 63117 ADVISORY COMMITTEE BRIEFING MATERIALS AVAILABLE FOR PUBLIC RELEASE Information provided within this briefing document is based upon medical and scientific information available to date. ADVISORY COMMITTEE BRIEFING MATERIALS AVAILABLE FOR PUBLIC RELEASE Page 1 / 168 Dotarem® (gadoterate meglumine) Injection – NDA# 204781 Advisory Committee Optimark® (gadoversetamide) Injection - NDAs# 020937, 020975 & 020976 Briefing Document EXECUTIVE SUMMARY Gadolinium-based contrast agents (GdCAs) are essential for use in magnetic resonance imaging (MRI). Although non-contrast-enhanced MRI may be sufficient for use in some clinical conditions, contrast-enhanced MRI (CE-MRI) using GdCA provides additional vital diagnostic information in a number of diseases. It is widely recognized that CE-MRI increases diagnostic accuracy and confidence, and thus can impact the medical and/or surgical management of patients. Based on the chemical structure of the complexing ligand, GdCA are classified as linear (L-GdCA) or macrocyclic (M-GdCA) and can be ionic or nonionic and those characteristics have a dramatic influence on the stability of the GdCA. Dotarem®, a M-GdCA, was first approved in France in 1989. US-FDA approval was obtained in March 2013 for “intravenous use with MRI of the brain (intracranial), spine and associated tissues in adult and pediatric patients (2 years of age and older) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity”, at the dose of 0.1 mmol/kg BW.